8-K: CyPath Lung Identifies Cancer in Ground-Glass Nodules

bioAffinity Technologies' CyPath Lung noninvasive diagnostic successfully identified lung cancer in a patient with difficult-to-diagnose ground-glass pulmonary nodules, shifting care from watchful waiting to immediate treatment.

Summary

• bioAffinity Technologies announced a new case study for its flagship product, CyPath Lung, a noninvasive diagnostic for lung cancer.
• CyPath Lung identified cancer in a 66-year-old former smoker who had incidental ground-glass lung nodules, which are typically challenging to assess.
• Ground-glass nodules often mimic benign lesions, do not typically light up on PET scans, and current society guidelines recommend 2-5 years of watchful waiting with serial CT scans.
• The patient's CyPath Lung test returned a likely malignant result, prompting robotic bronchoscopy which confirmed lung cancer, leading to immediate surgical treatment.
• CyPath Lung utilizes proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum indicative of malignancy.
• Clinical study results demonstrated CyPath Lung had 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with small lung nodules (less than 20 millimeters).

Sentiment

Score: 8

Explanation: The announcement presents a strong positive case study for CyPath Lung, demonstrating its efficacy in a challenging diagnostic scenario and highlighting its potential to improve patient outcomes and disrupt current diagnostic protocols. The clinical data also supports its high performance.

Positives

• CyPath Lung successfully identified lung cancer in a difficult-to-diagnose case involving ground-glass nodules, which are often subject to prolonged watchful waiting.
• The diagnostic provided actionable results, leading to timely treatment and potentially improved patient outcomes by avoiding years of uncertainty.
• The case study demonstrates CyPath Lung's value in the evaluation of both solid and sub-solid lung nodules, offering clarity where imaging and risk models are inconclusive.
• CyPath Lung's clinical study results show high performance: 92% sensitivity, 87% specificity, and 88% accuracy for early-stage lung cancer detection.
• The technology offers a noninvasive method for early detection, which can improve survival rates for lung cancer patients.

Risks

• Actual results could differ materially from current expectations due to various risks and uncertainties, many of which are difficult to predict.
• Important factors that could cause actual results to differ include the ability of CyPath Lung to consistently identify lung cancer in difficult-to-diagnose patients.
• The benefits of adding CyPath Lung to the standard of care for evaluating indeterminate lung nodules may not be realized as expected.
• CyPath Lung may not consistently provide clarity when imaging and risk models are inconclusive.
• Other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent SEC filings, could impact results.

Future Outlook

The company believes CyPath Lung can identify lung cancer in difficult-to-diagnose patients, provide benefits when added to the standard of care for evaluating indeterminate lung nodules, offer clarity when imaging and risk models are inconclusive, and provide significant value in the evaluation of both solid and sub-solid lung nodules. These forward-looking statements are based on current estimates and assumptions and are subject to various risks and uncertainties.

Management Comments

• "Adding CyPath Lung to the traditional standard of care can provide actionable results that move beyond watchful waiting to timely, potentially life-saving treatment." Gordon Downie, MD, PhD, Chief Medical Officer.
• "This case provides another real-world example of CyPath Lung’s value in the evaluation of both solid and sub-solid lung nodules by providing actionable information in real time that can help direct next steps in care, reduce uncertainty and improve patient outcomes." Maria Zannes, President and CEO.
• "CyPath Lung has the potential to significantly reduce the mystery of sub-solid, or ground-glass, nodules when they show up on imaging, and both patient and physician are reluctant to delay diagnosis." Maria Zannes, President and CEO.

Industry Context

The announcement highlights a significant challenge in lung cancer diagnosis: ground-glass nodules, which are difficult to assess and often lead to prolonged watchful waiting. CyPath Lung addresses a critical unmet need in the diagnostic market by offering a noninvasive solution that can provide earlier, actionable results, potentially disrupting the current standard of care for these specific types of nodules. This positions bioAffinity Technologies as an innovator in the early lung cancer detection space, particularly for challenging cases.

Comparison to Industry Standards

• Current society guidelines for ground-glass nodules recommend two to five years of watchful waiting with serial CT scans, which CyPath Lung aims to circumvent by providing earlier diagnostic clarity.
• Unlike PET scans, which typically do not 'light up' ground-glass nodules, CyPath Lung demonstrated success in identifying malignancy in such cases.
• The noninvasive nature of CyPath Lung contrasts with more invasive procedures that might be considered after prolonged watchful waiting or inconclusive imaging, offering a less burdensome option for patients.

Stakeholder Impact

• Shareholders: Positive impact due to demonstrated product efficacy, potential for increased market adoption, and validation of the company's technology.
• Patients: Significant positive impact through earlier and more accurate diagnosis of lung cancer, especially for difficult-to-assess ground-glass nodules, leading to timely, potentially life-saving treatment.
• Clinicians/Healthcare Providers: Provides a valuable new tool to reduce diagnostic uncertainty and improve patient management for challenging lung nodules, potentially shifting care from watchful waiting to proactive treatment.

Next Steps

• Continued marketing and adoption of CyPath Lung as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services.
• Further evaluation and potential integration of CyPath Lung into the standard of care for indeterminate lung nodules.

Key Dates

Recommendation

The filing provides compelling evidence of CyPath Lung's effectiveness in a challenging diagnostic area (ground-glass nodules), which represents a significant unmet medical need. The ability to shift care from years of watchful waiting to immediate, confirmed diagnosis and treatment is a strong value proposition. This successful case study, combined with previously reported high sensitivity, specificity, and accuracy, validates the company's technology and enhances its market potential. This positive development could lead to increased adoption and improved financial performance, making it an attractive investment.

Keywords

bioAffinity Technologies, CyPath Lung, lung cancer, noninvasive diagnostic, ground-glass nodules, biotechnology, early detection, cancer screening, AI diagnostic, flow cytometry